
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana has revised its 2025 earnings per share (EPS) estimate upward to $17.06, reflecting strong second-quarter results and updated guidance, indicating robust financial performance. The company anticipates year-over-year earnings growth for 2027 as margin initiatives are expected to take effect, despite assuming stability in Star ratings. Additionally, Humana's superior Medicare Advantage star rating positions it favorably in a competitive landscape, enhancing its resilience amid potential regulatory changes.
Bears say
The financial outlook for Humana appears negative due to anticipated declines in earnings per share (EPS) for 2026 compared to 2025, primarily influenced by ongoing challenges in Medicare Advantage (MA) and the competitive landscape. Additional risks include increased MA utilization, competition, inadequate reimbursement rates, and a potential decline in both Prescription Drug Plan (PDP) membership and MA Star ratings, which could further hinder growth in healthcare services. Furthermore, management's projections indicate that fiscal year 2027 EPS may fall short by approximately 10% due to necessary investments aimed at improving Star ratings, reflecting a concerning trend in the company’s financial performance.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares